Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. (Q54379716)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24382803

Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24382803

0 references

prostate cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Inge M. Van Oort

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24382803%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

9

object named as

Igle J de Jong

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24382803%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

5

object named as

Maartje Los

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24382803%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

author name string

Sushil Badrising

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24382803%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Vincent van der Noort

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24382803%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

H Pieter van den Berg

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24382803%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Paul Hamberg

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24382803%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Jules L Coenen

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24382803%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Alfons J M van den Eertwegh

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24382803%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Emile D Kerver

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24382803%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Harm van Tinteren

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24382803%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Andries M Bergman

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24382803%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

language of work or name

0 references

publication date

30 December 2013

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24382803

number of pages

8

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24382803%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

120

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24382803%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24382803%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

968-975

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24382803%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Estimates of the cancer incidence and mortality in Europe in 2006.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28518

7 January 2021

based on heuristic

inferred from DOI database lookup

Cancer treatment and survivorship statistics, 2012

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28518

7 January 2021

based on heuristic

inferred from DOI database lookup

The development of androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28518

7 January 2021

based on heuristic

inferred from DOI database lookup

Androgen receptor signaling in androgen-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28518

7 January 2021

based on heuristic

inferred from DOI database lookup

Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28518

7 January 2021

based on heuristic

inferred from DOI database lookup

In vivo amplification of the androgen receptor gene and progression of human prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28518

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased survival with enzalutamide in prostate cancer after chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28518

7 January 2021

based on heuristic

inferred from DOI database lookup

Abiraterone and increased survival in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28518

7 January 2021

based on heuristic

inferred from DOI database lookup

Enzalutamide--a major advance in the treatment of metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28518

7 January 2021

based on heuristic

inferred from DOI database lookup

Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28518

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28518

7 January 2021

based on heuristic

inferred from DOI database lookup

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28518

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28518

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28518

7 January 2021

based on heuristic

inferred from DOI database lookup

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28518

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular aspects of androgenic signaling and possible targets for therapeutic intervention in prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28518

7 January 2021

based on heuristic

inferred from DOI database lookup

Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28518

7 January 2021

based on heuristic

inferred from DOI database lookup

Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28518

7 January 2021

based on heuristic

inferred from DOI database lookup

Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28518

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28518

7 January 2021

based on heuristic

inferred from DOI database lookup

Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28518

7 January 2021

based on heuristic

inferred from DOI database lookup

Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28518

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.28518

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24382803%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24382803%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54379716&oldid=2255857401"